Generative‑AI drug companies continued to attract capital as Insilico moved toward a Hong Kong IPO and Edison Scientific closed a large seed round. Insilico filed to raise HK$2.27 billion (about US$292 million) to support clinical programs and further invest in generative AI and automated lab infrastructure. Edison Scientific, a new for‑profit spinout focused on research software and autonomous science, secured a $70 million seed round to build tools for accelerating discovery workflows. Both raises reflect investor appetite for platform‑driven AI approaches to drug discovery and lab automation. The financings will fund clinical advancement, model development and lab automation—resources that many AI‑driven biotechs say are essential to convert computational outputs into validated therapeutic candidates.